AtriCure, Inc. (ATRC)
USD 30.25
(-3.97%)
USD 30.25
(-3.97%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.1 Million USD | 61.84% |
| 2022 | -29.5 Million USD | 71.52% |
| 2021 | -36.85 Million USD | -238.65% |
| 2020 | -33.6 Million USD | -86.2% |
| 2019 | -21.51 Million USD | -183.72% |
| 2018 | -7.55 Million USD | 47.18% |
| 2017 | -15.48 Million USD | 27.42% |
| 2016 | -22.19 Million USD | -6.83% |
| 2015 | -20.6 Million USD | -76.44% |
| 2014 | -11.09 Million USD | -30.61% |
| 2013 | -8.85 Million USD | -67.41% |
| 2012 | -4.78 Million USD | -89.76% |
| 2011 | -2.68 Million USD | -246.33% |
| 2010 | -547.71 Thousand USD | -141.83% |
| 2009 | -13.32 Million USD | 124.3% |
| 2008 | -7.34 Million USD | 26.71% |
| 2007 | -10.24 Million USD | 16.44% |
| 2006 | -12.88 Million USD | -38.82% |
| 2005 | -8.67 Million USD | -99.0% |
| 2004 | -4.67 Million USD | -39.72% |
| 2003 | -3.35 Million USD | 40.71% |
| 2002 | -5.66 Million USD | -80.32% |
| 2001 | -3.14 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -6.46 Million USD | -102.3% |
| 2024 Q2 | -2.64 Million USD | 76.77% |
| 2024 Q3 | -936 Thousand USD | 42.08% |
| 2023 Q1 | -5.78 Million USD | -39.8% |
| 2023 Q4 | -4.48 Million USD | 44.5% |
| 2023 FY | - USD | 61.84% |
| 2023 Q2 | -4.14 Million USD | 28.33% |
| 2023 Q3 | -8.08 Million USD | -95.2% |
| 2022 Q2 | -10.75 Million USD | 4.46% |
| 2022 Q3 | -10.72 Million USD | 0.33% |
| 2022 Q4 | -4.13 Million USD | 61.43% |
| 2022 FY | - USD | 71.52% |
| 2022 Q1 | -11.26 Million USD | 9.93% |
| 2021 Q3 | -116.53 Million USD | -845.1% |
| 2021 Q1 | -15.88 Million USD | 9.24% |
| 2021 Q2 | -12.33 Million USD | 22.38% |
| 2021 FY | - USD | -238.65% |
| 2021 Q4 | -12.5 Million USD | 89.27% |
| 2020 Q4 | -17.5 Million USD | -338.56% |
| 2020 FY | - USD | -86.2% |
| 2020 Q1 | -15.45 Million USD | -19.4% |
| 2020 Q2 | -4.53 Million USD | 70.65% |
| 2020 Q3 | -3.99 Million USD | 12.0% |
| 2019 FY | - USD | -183.72% |
| 2019 Q2 | -1.47 Million USD | 52.23% |
| 2019 Q3 | -6.24 Million USD | -322.75% |
| 2019 Q4 | -12.94 Million USD | -107.29% |
| 2019 Q1 | -3.09 Million USD | -18.6% |
| 2018 Q2 | 3.16 Million USD | 143.73% |
| 2018 FY | - USD | 47.18% |
| 2018 Q4 | -2.6 Million USD | 31.57% |
| 2018 Q3 | -3.81 Million USD | -220.49% |
| 2018 Q1 | -7.23 Million USD | -5416.91% |
| 2017 Q2 | -4.01 Million USD | 45.0% |
| 2017 Q1 | -7.3 Million USD | 5.11% |
| 2017 FY | - USD | 27.42% |
| 2017 Q4 | 136 Thousand USD | 101.99% |
| 2017 Q3 | -6.84 Million USD | -70.49% |
| 2016 Q3 | -3.89 Million USD | 28.21% |
| 2016 Q1 | -7.24 Million USD | 15.35% |
| 2016 FY | - USD | -6.83% |
| 2016 Q2 | -5.42 Million USD | 25.19% |
| 2016 Q4 | -7.69 Million USD | -97.66% |
| 2015 Q2 | -3.43 Million USD | 10.33% |
| 2015 FY | - USD | -76.44% |
| 2015 Q3 | -4.6 Million USD | -34.07% |
| 2015 Q4 | -8.56 Million USD | -85.85% |
| 2015 Q1 | -3.83 Million USD | -10.27% |
| 2014 Q1 | -6.84 Million USD | -59.7% |
| 2014 FY | - USD | -30.61% |
| 2014 Q2 | -1.72 Million USD | 74.84% |
| 2014 Q4 | -3.47 Million USD | -870.73% |
| 2014 Q3 | 451 Thousand USD | 126.21% |
| 2013 Q2 | -1.15 Million USD | 13.52% |
| 2013 Q1 | -1.33 Million USD | 27.7% |
| 2013 Q4 | -4.28 Million USD | -63.85% |
| 2013 Q3 | -2.61 Million USD | -125.73% |
| 2013 FY | - USD | -67.41% |
| 2012 Q3 | -2.05 Million USD | -176.9% |
| 2012 Q4 | -1.85 Million USD | 10.05% |
| 2012 Q2 | -743.58 Thousand USD | 22.96% |
| 2012 FY | - USD | -89.76% |
| 2012 Q1 | -965.12 Thousand USD | 23.55% |
| 2011 Q1 | -540.19 Thousand USD | -252.65% |
| 2011 Q4 | -1.26 Million USD | -63.64% |
| 2011 FY | - USD | -246.33% |
| 2011 Q3 | -771.47 Thousand USD | -253.29% |
| 2011 Q2 | -218.36 Thousand USD | 59.58% |
| 2010 Q4 | 353.88 Thousand USD | 223.47% |
| 2010 Q2 | 179.36 Thousand USD | 117.03% |
| 2010 Q3 | -286.62 Thousand USD | -259.8% |
| 2010 Q1 | -1.05 Million USD | 28.91% |
| 2010 FY | - USD | -141.83% |
| 2009 Q1 | -517.89 Thousand USD | 74.67% |
| 2009 Q4 | -1.48 Million USD | 61.24% |
| 2009 Q3 | -3.82 Million USD | -822.65% |
| 2009 Q2 | -414.17 Thousand USD | 20.03% |
| 2009 FY | - USD | 124.3% |
| 2008 Q3 | -1.21 Million USD | 9.28% |
| 2008 FY | - USD | 26.71% |
| 2008 Q1 | -3.32 Million USD | -288.57% |
| 2008 Q2 | -1.34 Million USD | 59.63% |
| 2008 Q4 | -2.04 Million USD | -67.83% |
| 2007 Q1 | -4.78 Million USD | -21.74% |
| 2007 FY | - USD | 16.44% |
| 2007 Q2 | -2.81 Million USD | 41.27% |
| 2007 Q4 | -856.31 Thousand USD | 63.82% |
| 2007 Q3 | -2.36 Million USD | 15.85% |
| 2006 FY | - USD | -38.82% |
| 2006 Q1 | -2.94 Million USD | 22.61% |
| 2006 Q2 | -3.16 Million USD | -7.65% |
| 2006 Q3 | -2.91 Million USD | 8.11% |
| 2006 Q4 | -3.93 Million USD | -35.14% |
| 2005 Q3 | -3.42 Million USD | -233.37% |
| 2005 Q4 | -3.8 Million USD | -11.06% |
| 2005 Q1 | -1.11 Million USD | 50.68% |
| 2005 FY | - USD | -99.0% |
| 2005 Q2 | -1.02 Million USD | 7.63% |
| 2004 FY | - USD | -39.72% |
| 2004 Q4 | -2.25 Million USD | -52.62% |
| 2004 Q2 | -250.41 Thousand USD | 0.0% |
| 2004 Q3 | -1.47 Million USD | -489.98% |
| 2003 FY | - USD | 40.71% |
| 2002 FY | - USD | -80.32% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 82.23% |
| AngioDynamics, Inc. | -14.29 Million USD | 43.262% |
| Avinger, Inc. | -16.34 Million USD | 50.392% |
| Azenta, Inc. | 55.15 Million USD | 114.703% |
| BioLife Solutions, Inc. | -45.23 Million USD | 82.075% |
| The Cooper Companies, Inc. | 882.8 Million USD | 100.919% |
| Daxor Corporation | 329.74 Thousand USD | 2559.21% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | 38.559% |
| Femasys Inc. | -13.16 Million USD | 38.425% |
| GlucoTrack, Inc. | -7.09 Million USD | -14.356% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 185.421% |
| Hologic, Inc. | 1.29 Billion USD | 100.626% |
| ICU Medical, Inc. | 307.69 Million USD | 102.635% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.339% |
| KORU Medical Systems, Inc. | -9.39 Million USD | 13.73% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 116.552% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -23.328% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -23.328% |
| Masimo Corporation | 236.7 Million USD | 103.426% |
| Microbot Medical Inc. | -10.63 Million USD | 23.745% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 151.419% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 103.504% |
| Nephros, Inc. | -1.37 Million USD | -488.035% |
| NovoCure Limited | -175.86 Million USD | 95.389% |
| NEXGEL, Inc. | -2.73 Million USD | -197.033% |
| NEXGEL, Inc. | -2.73 Million USD | -197.033% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 90.625% |
| OraSure Technologies, Inc. | 76.15 Million USD | 110.648% |
| Pro-Dex, Inc. | 8.33 Million USD | 197.312% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 80.86% |
| Predictive Oncology Inc. | -13.18 Million USD | 38.484% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -222.817% |
| QuidelOrtho Corporation | 545.6 Million USD | 101.486% |
| Repligen Corporation | 124.29 Million USD | 106.524% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -2704.941% |
| STAAR Surgical Company | 33.22 Million USD | 124.409% |
| Sharps Technology, Inc. | -8.98 Million USD | 9.703% |
| Utah Medical Products, Inc. | 24.8 Million USD | 132.691% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 103.495% |
| Jin Medical International Ltd. | 3.44 Million USD | 335.529% |